Juvenile myoclonic epilepsy (JME) is characterized by seizures, severe cognitive abnormalities, and behavior impairments. These features could evolve over time and get worse, especially when the encephalopathy is pharmacoresistant. Thus, genetic studies should provide a better understanding of infantile epilepsy syndromes. Herein, we investigate the genetics of JME in a consanguineous family analyzing the copy number variations detected using over 700 K SNP arrays. We identified a 254-kb deletion in the 22q11.2 region, including only the TOP3B gene, detected in the patient and her father. TOP3B encodes a topoisomerase DNA (III) β protein and has been implicated in several neurological diseases such as schizophrenia and autism. In this study, we discuss the implication of the 22q11.2 region in neurodevelopmental disorders and the association of TOP3B with epilepsy.

Alemany S, Ribasés M, Vilor-Tejedor N, Bustamante M, Sánchez-Mora C, et al: New suggestive genetic loci and biological pathways for attention function in adult attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 168:459-470 (2015).
Ben-Shachar S, Ou Z, Shaw CA, Belmont JW, Patel MS, et al: 22q11.2 distal deletion: a recurrent genomic disorder distinct from DiGeorge syndrome and velocardiofacial syndrome. Am J Hum Genet 82:214-221 (2008).
Delgado-Escueta AV: Advances in genetics of juvenile myoclonic epilepsies. Epilepsy Curr 7:61-67 (2007).
Delgado-Escueta AV, Koeleman BP, Bailey JN, Medina MT, Durón RM: The quest for juvenile myoclonic epilepsy genes. Epilepsy Behav 28 Suppl 1:S52-57 (2013).
Escayg A, De Waard M, Lee DD, Bichet D, Wolf P, et al: Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 66:1531-1539 (2000).
Helbig I, Sammler E, Eliava M, Bolshakov AP, Rozov A, et al: In vivo evidence for the involvement of the carboxy terminal domain in assembling connexin 36 at the electrical synapse. Mol Cell Neurosci 45:47-58 (2010).
Hu Y, Zhu X, Yang Y, Mo X, Sheng M, et al: Incidences of micro-deletion/duplication 22q11.2 detected by multiplex ligation-dependent probe amplification in patients with congenital cardiac disease who are scheduled for cardiac surgery. Cardiol Young 19:179-184 (2009).
Jiramongkolchai P, Kumar MS, Chinnadurai S, Wootten CT, Goudy SL: Prevalence of hearing loss in children with 22q11.2 deletion syndrome. Int J Pediatr Otorhinolaryngol 87:130-133 (2016).
Kao A, Mariani J, McDonald-McGinn DM, Maisenbacher MK, Brooks-Kayal AR, et al: Increased prevalence of unprovoked seizures in patients with a 22q11.2 deletion. Am J Med Genet A 129A:29-34 (2004).
Karayiorgou M, Simon TJ, Gogos JA: 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat Rev Neurosci 11:402-416 (2010).
Kaufman CS, Genovese A, Butler MG: Deletion of TOP3B is associated with cognitive impairment and facial dysmorphism. Cytogenet Genome Res 150:106-111 (2016).
Kim EH, Yum MS, Lee BH, Kim HW, Lee HJ, et al: Epilepsy and other neuropsychiatric manifestations in children and adolescents with 22q11.2 deletion syndrome. J Clin Neurol 12:85-92 (2016).
Koepp MJ, Thomas RH, Wandschneider B, Berkovic SF, Schmidt D: Concepts and controversies of juvenile myoclonic epilepsy: still an enigmatic epilepsy. Expert Rev Neurother 14:819-931 (2014).
Lemke JR, Beck-Wödl S, Zankl A, Riegel M, Krämer G, Dorn T: Juvenile myoclonic epilepsy with photosensitivity in a female with velocardiofacial syndrome (del(22)(q11.2)) - causal relationship or coincidence? Seizure 18:660-663 (2009).
Robin NH, Taylor CJ, McDonald-McGinn DM, Zackai EH, Bingham P, et al: Polymicrogyria and deletion 22q11.2 syndrome: window to the etiology of a common cortical malformation. Am J Med Genet A 140:2416-2425 (2006).
Rødningen OK, Prescott T, Eriksson AS, Røsby O: 1.4 Mb recurrent 22q11.2 distal deletion syndrome, two new cases expand the phenotype. Eur J Med Genet 51:646-650 (2008).
Stoll G, Pietiläinen OPH, Linder B, Suvisaari J, Brosi C, et al: Deletion of TOP3β, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. Nat Neurosci 16:1228-1237(2013).
Strehlow V, Swinkels ME, Thomas RH, Rapps N, Syrbe S, et al: Generalized epilepsy and myoclonic seizures in 22q11.2 deletion syndrome. Mol Syndromol 7:239-246 (2016).
Tang KL, Antshel KM, Fremont WP, Kates WR: Behavioral and psychiatric phenotypes in 22q11.2 deletion syndrome. J Dev Behav Pediatr 36:639-650 (2015).
Thomas RH, Berkovic SF: The hidden genetics of epilepsy-a clinically important new paradigm. Nat Rev Neurol 10:283-292 (2014).
Wenger TL, Miller JS, DePolo LM, de Marchena AB, Clements CC, et al: 22q11.2 duplication syndrome: elevated rate of autism spectrum disorder and need for medical screening. Mol Autism 7:27 (2016).
Wight JE, Nguyen VH, Medina MT, Patterson C, Durón RM, et al: Chromosome loci vary by juvenile myoclonic epilepsy subsyndromes: linkage and haplotype analysis applied to epilepsy and EEG 3.5-6.0 Hz polyspike waves. Mol Genet Genomic Med 4:197-210 (2016).
Xu D, Shen W, Guo R, Xue Y, Peng W, et al: Top3β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. Nat Neurosci 16:1238-1247 (2013).
Xu J, Fan YS, Siu VM: A child with features of Goldenhar syndrome and a novel 1.12 Mb deletion in 22q11.2 by cytogenetics and oligonucleotide array CGH: is this a candidate region for the syndrome? Am J Med Genet A 146A:1886-1889 (2008).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.